308 related articles for article (PubMed ID: 16597474)
1. Phase II study of pegylated liposomal doxorubicin HCl (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small cell lung cancer.
Leighl NB; Goss GD; Lopez PG; Burkes RL; Dancey JE; Rahim YH; Rudinskas LC; Pouliot JF; Rodgers A; Pond GR; Shepherd FA
Lung Cancer; 2006 Jun; 52(3):327-32. PubMed ID: 16597474
[TBL] [Abstract][Full Text] [Related]
2. A Phase II trial of pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone combination therapy in newly diagnosed multiple myeloma patients.
Hussein MA; Wood L; Hsi E; Srkalovic G; Karam M; Elson P; Bukowski RM
Cancer; 2002 Nov; 95(10):2160-8. PubMed ID: 12412170
[TBL] [Abstract][Full Text] [Related]
3. A phase I study of pegylated liposomal doxorubicin hydrochloride (Caelyx) in combination with cyclophosphamide and vincristine as second-line treatment of patients with small-cell lung cancer.
Leighl NB; Burkes RL; Dancey JE; Lopez PG; Higgins BP; David Walde PL; Rudinskas LC; Rahim YH; Rodgers A; Pond GR; Shepherd FA
Clin Lung Cancer; 2003 Sep; 5(2):107-12. PubMed ID: 14596693
[TBL] [Abstract][Full Text] [Related]
4. Pegylated Liposomal Doxorubicin HCL (Caelyx) in combination with Sandostatin LAR as salvage therapy in patients with small-cell lung cancer.
Charpidou A; Hatzidarellis EP; Alamara C; Dilana K; Pantazopoulos K; Kotteas E; Georgatou N; Syrigos KN
In Vivo; 2006; 20(4):553-7. PubMed ID: 16900789
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer.
Gandhi L; Harding MW; Neubauer M; Langer CJ; Moore M; Ross HJ; Johnson BE; Lynch TJ
Cancer; 2007 Mar; 109(5):924-32. PubMed ID: 17285598
[TBL] [Abstract][Full Text] [Related]
6. Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer.
Shepherd FA; Evans WK; MacCormick R; Feld R; Yau JC
Cancer Treat Rep; 1987 Oct; 71(10):941-4. PubMed ID: 2820571
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas.
Nielsen OS; Reichardt P; Christensen TB; Pink D; Daugaard S; Hermans C; Marreaud S; van Glabbeke M; Blay J; Judson I
Eur J Cancer; 2006 Sep; 42(14):2303-9. PubMed ID: 16891112
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma.
Wang M; Fayad L; Cabanillas F; Hagemeister F; McLaughlin P; Rodriguez MA; Kwak LW; Zhou Y; Kantarjian H; Romaguera J
Cancer; 2008 Nov; 113(10):2734-41. PubMed ID: 18973182
[TBL] [Abstract][Full Text] [Related]
9. Pilot study with weekly chemotherapy for patients with extensive small cell lung cancer: an Eastern Cooperative Oncology Group Study (PA586).
Yuen AR; Fuks JZ; Ettinger DS; Chang AY; Ruckdeschel JC; Phan SC; Blum RH
Cancer J Sci Am; 2000; 6(1):34-9. PubMed ID: 10696737
[TBL] [Abstract][Full Text] [Related]
10. Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
Sundstrøm S; Bremnes RM; Kaasa S; Aasebø U; Aamdal S;
Lung Cancer; 2005 May; 48(2):251-61. PubMed ID: 15829326
[TBL] [Abstract][Full Text] [Related]
11. Dose-intensive weekly alternating chemotherapy for patients with small cell lung cancer: randomized trial, can it improve survival of patients with good prognostic factors?
Masutani M; Ochi Y; Kadota A; Akusawa H; Kisohara A; Takahashi N; Koya Y; Horie T
Oncol Rep; 2000; 7(2):305-10. PubMed ID: 10671676
[TBL] [Abstract][Full Text] [Related]
12. Oral second- and third-line lomustine-etoposide-cyclophosphamide chemotherapy for small cell lung cancer.
Lebeau B; Chouaïd C; Baud M; Masanès MJ; Febvre M
Lung Cancer; 2010 Feb; 67(2):188-93. PubMed ID: 19394109
[TBL] [Abstract][Full Text] [Related]
13. [Adriamycin, cyclophosphamide, vincristine and methotrexate combination chemotherapy of small cell lung cancer].
Saito H; Kawatsu H; Saka H; Yamamoto M; Takagi E; Tsunekawa H; Kawachi H; Nagura E; Sakai S; Nishiwaki K
Gan To Kagaku Ryoho; 1988 Jun; 15(6):1909-13. PubMed ID: 2838000
[TBL] [Abstract][Full Text] [Related]
14. [Pilot phase II study of hybrid chemotherapy of CAV-PVP in small cell lung cancer (SCLC)].
Ueoka H; Ohnoshi T; Hiraki S; Kawahara S; Numata T; Nishii K; Yonei T; Yamashita H; Moritaka T; Kiura K
Gan To Kagaku Ryoho; 1989 Jun; 16(6):2251-5. PubMed ID: 2544149
[TBL] [Abstract][Full Text] [Related]
15. Sequential salvage chemotherapy for recurrent intracranial hemangiopericytoma.
Chamberlain MC; Glantz MJ
Neurosurgery; 2008 Oct; 63(4):720-6; author reply 726-7. PubMed ID: 18981882
[TBL] [Abstract][Full Text] [Related]
16. [Cyclophosphamide, adriamycin and vincristine (CAV) in the treatment of small cell lung cancer].
Kawahara M; Tsuruta M; Furuse K; Arai R; Kodama N; Yamamoto M; Kubota K; Nakai R; Ogawara M
Gan To Kagaku Ryoho; 1988 Mar; 15(3):457-62. PubMed ID: 2831819
[TBL] [Abstract][Full Text] [Related]
17. Combination versus alternating chemotherapy in small-cell lung cancer.
Lai SL; Perng RP
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jul; 63(7):513-20. PubMed ID: 10934803
[TBL] [Abstract][Full Text] [Related]
18. Cisplatin and etoposide alternating with vincristine, doxorubicin and cyclophosphamide in patients with small cell lung cancer.
Littlewood TJ; Smith AP; Anderson G; Chappell AG; James KW
Eur J Respir Dis; 1985 Oct; 67(4):294-300. PubMed ID: 3000808
[TBL] [Abstract][Full Text] [Related]
19. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study.
Sehouli J; Camara O; Schmidt M; Mahner S; Seipelt G; Otremba B; Schmalfeldt B; Tesch H; Lorenz-Schlüter C; Oskay-Ozcelik G;
Cancer Chemother Pharmacol; 2009 Aug; 64(3):585-91. PubMed ID: 19156414
[TBL] [Abstract][Full Text] [Related]
20. Hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) combined with vinorelbine and liposomal doxorubicin for locally advanced non-small cell lung cancer (NSCLC).
Tsoutsou PG; Froudarakis ME; Bouros D; Koukourakis MI
Anticancer Res; 2008; 28(2B):1349-54. PubMed ID: 18505077
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
